Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

LOU GEHRIG'S DISEASE - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Lou Gehrig's Disease in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 39 companies including many key and niche players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd., Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Inc., Knopp Neurosciences, Maas Biolab, NeuroNova AB, Sygnis Pharma AG, Teva Pharmaceutical Industries Ltd., and Trophos SA. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6016
Price : $3450
Companies : 39
Pages : 253
Date : April 2010
Market Data Tables : 76

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  LOU GEHRIG'S DISEASE (Complete Report) Pages : 253   | $3450
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS    
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
II. EXECUTIVE SUMMARY30$2500
  1. INDUSTRY OVERVIEW.....II-13 $495  
   Global Market Analysis.....II-1
Sanofi-Aventis – The Only Drug Maker for ALS.....II-1
Rilutek.....II-1
1$100
   Prevalence and Incidence of ALS.....II-2
The United States.....II-2
Canada.....II-2
1$100
   Table 1: Mortality Rate of ALS in Canada - A Historic Review (includes corresponding Graph/Chart).....II-3
The United Kingdom.....II-3
New Zealand.....II-3
Australia.....II-3
Table 2: Mortality Rate in Australia for Years 2005 through 2007(includes corresponding Graph/Chart).....II-3
1$350
  2. AMYOTROPHIC LATERAL SCLEROSIS – AN INSIGHT.....II-47 $595  
   Major Types of ALS.....II-41$100
   Etiology.....II-51$100
   Exact Causes of ALS Still Unknown.....II-6
Major Milestones in ALS Treatment Arena.....II-6
Diagnosis.....II-6
1$100
   Symptoms of ALS.....II-7
Initial symptoms.....II-7
1$100
   Emerging Symptoms.....II-8
Use of BiPAP, IPPV and Mechanical Respirators in ALS.....II-8
Measures to Deal with ALS Problems.....II-8
1$100
   Treatment.....II-9
Symptomatic Treatment.....II-9
2$200
  3. POTENTIAL THERAPIES FOR ALS.....II-114 $295  
   Neurotrophic Factors.....II-11
Insulin-like Growth Factor.....II-11
Vascular endothelial growth factor.....II-11
Sangamo BioSciences to Develop SB 509.....II-11
1$100
   Smaller Molecules.....II-12
RNA Interference.....II-12
Stem Cells Offer New Hope.....II-12
Studies on Stem Cells.....II-12
1$100
   LTC to Develop New Lou Gehrig's Disease Models.....II-13
Herbal Treatment.....II-13
Lithium: A potential Treatment for ALS.....II-13
Advancements in ALS Genetics.....II-13
1$100
   Select Pipeline Drugs for ALS Under Clinical Trials (2009).....II-141$100
  4. CLINICAL TRIALS AND RESEARCH STUDIES.....II-152 $200  
   CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol.....II-15
New Treatment for ALS Patients.....II-15
KNS-760704 Receives Orphan Designation.....II-15
KNS-760704 Enters Phase 2 Study.....II-15
1$100
   Maas Biolab SBIR Initiates Phase 2 for Cyclosporin.....II-16
Researchers Identify New Gene for ALS.....II-16
1$100
  5. RECENT INDUSTRY ACTIVITY.....II-176 $495  
   Merck to Purchase Insmed’s Assets.....II-17
NeuroNova Signs Agreement with Genentech.....II-17
Insmed Inks a Deal with IDIS to Organize NPPs for IPLEX™.....II-17
1$100
   Teva to Extend Branded Products in Niche Specialty Diseases.....II-18
Asklepios and ALS TDI Develop Latest Therapeutic Delivery Alternatives for ALS
  Treatment.....II-18
Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular Disorders.....II-18
Neuralstem and Hospital of Taiwan Collaborate for Development of Neural Stem Cell
  Therapies.....II-18
1$100
   Life Technologies to Create Neurodegenerative Disease Models.....II-19
Medicare Extends the Coverage of HFCWO to Cure Neuromuscular Disorders.....II-19
Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord Injury Treatment.....II-19
Insmed Obtains Royalty-Free Global Rights for IPLEXTM.....II-19
1$100
   Q Therapeutics Collaborates with Johns Hopkins Research Team.....II-20
Aldagen to Collaborate with UC Davis.....II-20
ALS TDI Collaborates with CSC.....II-20
ALS TDI and Allen Institute for Brain Science Enter into Agreement.....II-20
1$100
   Amorfix Completes Research Partnership with Biogen Idec.....II-21
Isis Receives Orphan Drug Designation.....II-21
Prize4Life Endorses BrainStorm to Develop ALS Cure.....II-21
1$100
   ALS TDI Selects Microbix to Manufacture Adenoviruses.....II-22
Maas BiolAB Receives SBIR Grant.....II-22
Neuralstem Collaborates with University of Michigan.....II-22
ALS TDI and MDA Collaborate.....II-22
1$100
  6. PLAYERS VENTURING THE ALS MARKET.....II-234 $295  
   Aeolus Pharmaceuticals, Inc. (US).....II-23
Amorfix Life Sciences Ltd. (Canada).....II-23
Avicena Group, Inc. (US).....II-23
Ceregene, Inc. (US).....II-23
1$100
   CytRx Corporation (US).....II-24
Genzyme Corporation (US).....II-24
Isis Pharmaceuticals, Inc. (US).....II-24
1$100
   Knopp Neurosciences (US).....II-25
Maas Biolab (US).....II-25
NeuroNova AB (Sweden).....II-25
1$100
   Sygnis Pharma AG (Germany).....II-26
Teva Pharmaceutical Industries Ltd. (Israel).....II-26
Trophos SA (France).....II-26
1$100
  7. ASSOCIATIONS INVOLVED IN ALS RESEARCH.....II-272 $200  
   Northeast Amyotrophic Lateral Sclerosis Consortium (US).....II-27
Muscular Dystrophy Association (MDA).....II-27
The ALS Association.....II-27
ALS Society of Canada.....II-27
ALS Therapy Development Institute.....II-27
1$100
   Motor Neurone Disease Research Institute of Australia.....II-281$100
  8. GLOBAL MARKET PERSPECTIVE.....II-29   
   Table 3: World Recent Past, Current & Future Analysis for Lou Gehrig's Disease by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-291$350
   Table 4: World 10-Year Perspective for Lou Gehrig's Disease by Geographic Region – Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-301$350
III. COMPETITIVE LANDSCAPE 214$995
  
Total Companies Profiled: 39 (including Divisions/Subsidiaries - 40)

Region/Country                 Players


The United States                 30   
Canada                             2
Japan                              1
Europe                             6
     France                        2
     Germany                       1
     The United Kingdom            1
     Rest of Europe                2
Middle-east                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign